Appendiceal tumor incidence and an in-depth look at appendiceal neuroendocrine neoplasm in a cohort of 8,162 appendectomies: Full dataset
Rachel Chava Rosenblum,
Noa Klein,
Haim Paran,
Shmuel Avital,
Vladimir Kravtsov,
Pnina Rotman-Pikielny,
Orit Twito
Affiliations
Rachel Chava Rosenblum
Institute of Endocrinology, Diabetes and Metabolism, Meir Medical Center, Kfar- Sava, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Corresponding author.
Noa Klein
Institute of Endocrinology, Diabetes and Metabolism, Meir Medical Center, Kfar- Sava, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Haim Paran
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Department of Surgery A, Meir Medical Center, Kfar- Sava, Israel
Shmuel Avital
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Department of Surgery B, Meir Medical Center, Kfar- Sava, Israel
Vladimir Kravtsov
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Department of Pathology, Meir Medical Center, Kfar- Sava, Israel
Pnina Rotman-Pikielny
Institute of Endocrinology, Diabetes and Metabolism, Meir Medical Center, Kfar- Sava, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Orit Twito
Institute of Endocrinology, Diabetes and Metabolism, Meir Medical Center, Kfar- Sava, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Data describing appendiceal tumor incidence and epidemiology is limited. We collated data from appendectomy pathology reports between 2005 and 2018 in our institution and examined patient epidemiological and appendectomy pathological features [1]. Overall, 8,328 appendectomies were performed at our institution over the pre-specified time period and 8,162 patients had sufficient epidemiological data to be included in the analysis. A total of 153 patients (1.9%) were diagnosed with appendiceal tumors, of which 57 (37.3%) were Appendiceal Neuroendocrine Neoplasm (ANEN), 35 (22.9%) were mucinous cystadenoma and 34 (22.2%) ovarian cancer metastases. We further examined the ANEN cases in order to characterize initial patient and tumor characteristics, to evaluate the performance of further investigations and interventions, and ultimately to study the behavior of these tumors over time.